336882-83-8

Basic information

• Product Name: Benzeneacetic acid, a-(2-bromoethyl)-a-phenyl-, methyl ester
• CAS NO: 336882-83-8
• Molecular Formula: C17H17BrO2
• Molecular Weight: 333.225
• Mol File: 336882-83-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, a-(2-bromoethyl)-a-phenyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, a-(2-bromoethyl)-a-phenyl-, methyl ester(336882-83-8)
• EPA Substance Registry System: Benzeneacetic acid, a-(2-bromoethyl)-a-phenyl-, methyl ester(336882-83-8)

Safety Data

• Hazardous Substances Data: 336882-83-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 37742-98-6 4-Bromo-2,2-diphenylbutyric acid 
• 50650-44-7 4-bromo-2,2-diphenylbutyric acid chloride 

Downstream Products

• 794591-41-6 4-[4-hydroxy-4-(3-trifluoromethyl-phenyl)-piperidin-1-yl]-2,2-diphenyl-butyric acid methyl ester 
• 794591-42-7 4-[4-(4-chloro-3-trifluoromethyl-phenyl)-4-hydroxy-piperidin-1-yl]-2,2-diphenyl-butyric acid methyl ester 
• 786595-16-2 methyl 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-2,2-diphenylbutanoate 
• 33802-52-7 2,2-diphenyl-4-oxo-butyric acid methyl ester 

Relevant articles and documents

A facile synthesis for novel loperamide analogs as potential μ opioid receptor agonists

A facile synthesis for novel loperamide analogs as potential μ opioid receptors is described. The synthetic procedure for compound 5, which contains two 4-phenyl piperidine scaffolds, was optimized, and this compound was synthesized in excellent yield. We

Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor

Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series. Small molecule mu agonists based on the 4-phenyl piperidine scaffold were designed and synthesized to further investigate the therapeutic potential of loperamide analogs. The resulting compounds show excellent agonistic activity towards the human mu receptor with interesting SAR trends within the series.